Literature DB >> 8417827

BR96 sFv-PE40, a potent single-chain immunotoxin that selectively kills carcinoma cells.

P N Friedman1, S J McAndrew, S L Gawlak, D Chace, P A Trail, J P Brown, C B Siegall.   

Abstract

We have constructed a single-chain immunotoxin composed of the carcinoma-reactive antibody BR96 and a truncated form of Pseudomonas exotoxin. The chimeric molecule, BR96 sFv-PE40, was expressed in Escherichia coli and localized to the inclusion bodies. We purified and identified two species of BR96 sFv-PE40, monomers and aggregates. The monomeric form was able to bind well to the BR96 antigen, a Lewisy-related antigen, while the aggregate was not. The binding affinity of the monomeric recombinant immunotoxin was 5-fold less than intact BR96 IgG, and its specificity for the BR96 antigen was confirmed by competition analysis. Monomeric BR96 sFv-PE40 was found to be extremely cytotoxic against cancer cells displaying the BR96 antigen. The cytotoxicity of the fusion protein correlates directly with antigen density on the tumor cell lines tested. The breast carcinoma cell line MCF-7, which has the highest density of BR96 antigen, was the most sensitive to BR96 sFv-PE40, with a concentration producing 50% protein synthesis inhibition of 5 pM. BR96 sFv-PE40 was found to have a t1/2 in serum of 28.5 min in athymic mice, compared to that of the chemical conjugate, chiBR96-LysPE40, which was 54 min. These data indicate that the single-chain immunotoxin BR96 sFv-PE40 is a potent inhibitor of protein synthesis in target cell lines and may be an effective agent for the treatment of cancer.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8417827

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   13.312


  4 in total

1.  Bacterial aspects associated with the expression of a single-chain antibody fragment in Escherichia coli.

Authors:  J E Somerville; S C Goshorn; H P Fell; R P Darveau
Journal:  Appl Microbiol Biotechnol       Date:  1994-12       Impact factor: 4.813

Review 2.  Clinical targeting recombinant immunotoxins for cancer therapy.

Authors:  Meng Li; Zeng-Shan Liu; Xi-Lin Liu; Qi Hui; Shi-Ying Lu; Lin-Lin Qu; Yan-Song Li; Yu Zhou; Hong-Lin Ren; Pan Hu
Journal:  Onco Targets Ther       Date:  2017-07-20       Impact factor: 4.147

3.  Affitoxin--a novel recombinant, HER2-specific, anticancer agent for targeted therapy of HER2-positive tumors.

Authors:  Rafal Zielinski; Ilya Lyakhov; Amy Jacobs; Oleg Chertov; Gabriela Kramer-Marek; Nicholas Francella; Andrew Stephen; Robert Fisher; Robert Blumenthal; Jacek Capala
Journal:  J Immunother       Date:  2009-10       Impact factor: 4.912

4.  Bioinformatic analysis of the expression and prognosis of ZNF589 in human breast cancer.

Authors:  Jun Fan; Zhe Zhang; Dongjiao Chen; Hongqiang Chen; Wenbo Yuan; Lu Zhou; Jing Xu; Wenbin Liu; Yan Xu
Journal:  Transl Cancer Res       Date:  2021-05       Impact factor: 1.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.